Amarin is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular disease. The Company is focusing its studies on AMR101 (icosapent ethyl), a prescription-only omega-3 fatty acid. The Company is developing AMR101 for the treatment of patients with very high triglyceride levels and high triglyceride levels, or hypertriglyceridemia. Triglycerides are fats in the blood.Data provided by Mergent, Inc.
|DR Exchange||NASDAQ Stock Market|
|Effective Date||Apr 08, 1993|
|Industry||Pharma. & Biotech.|
This DR is a Constituent of the following BNY Mellon DR Indices: